Follistatin 344 is a follistatin isoform studied preclinically as an inhibitor of myostatin and activin. This page describes hypothesized and investigational effects, not established treatments.
Overview
Follistatin 344 (FST-344) is a secreted protein that binds and neutralizes members of the TGF-beta superfamily, especially myostatin and activin. Because myostatin acts as a natural brake on muscle growth, interest in follistatin centers on:
- Inhibiting myostatin to release a natural limit on muscle growth.
- Binding activin, which has broad roles beyond muscle.
- Downstream effects on pathways governing muscle protein balance.
These are the mechanisms researchers study; they are not a promise of any specific athletic, cosmetic, or clinical result in humans.
Myostatin inhibition and muscle
In cell and animal models, reducing myostatin activity is associated with increased muscle mass, which is the central reason follistatin attracts attention. It is worth stressing that follistatin is the inhibitor, not myostatin itself — a distinction that is frequently confused in popular discussion.
- Follistatin sequesters myostatin so it cannot signal through its receptor.
- The effect is upstream of muscle-growth regulation rather than a direct anabolic hormone.
- Human translation of these mechanisms remains uncertain.
Muscle-wasting research interest
Because myostatin inhibition is a plausible strategy against muscle loss, follistatin has been explored preclinically in the context of muscular dystrophies and other muscle-wasting conditions, including both recombinant protein and gene-therapy approaches. This is the research setting most relevant to its scientific interest.
How follistatin is framed
Follistatin is often discussed alongside related concepts, but important distinctions apply:
- Follistatin vs myostatin — follistatin inhibits; myostatin is the growth-limiting signal.
- FST-344 vs FST-315 — isoforms differing at the C-terminus, affecting binding and distribution.
- Protein vs gene therapy — very different delivery and exposure profiles in research.
Evidence and caveats
Follistatin has well-described mechanisms, but that is not the same as proven benefit for muscle, performance, or appearance in people. Key caveats:
- It is not an FDA-approved therapy.
- Most supportive data are preclinical, and delivery is a major unsolved challenge.
- Myostatin inhibitors are prohibited in sport.
- Long-term safety in healthy people has not been established.